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Abstract
Background: Unsaturated fatty acids (UFAs) exhibit in vitro cytotoxicity against many malignant
cell lines and yield decreased cancer incidence and reduced tumor growth in animal models. But
clinical and animal studies to date have achieved response using only localized delivery methods
such as intratumoral infusion. To explore possibilities for enhanced clinical efficacy, fresh surgical
explants of tumors from 22 patients with five malignancies were exposed to γ-linolenic acid (GLA)
and α-linolenic acid (ALA) and analyzed with an in vitro chemosensitivity testing system, the
Fluorescent Cytoprint Assay (FCA). A total of 282 micro-organ cultures derived from these
malignant tumors were exposed to GLA and ALA at different concentrations.
Results: GLA and ALA exhibited greater than 90% cytotoxicity at a sharp concentration threshold
between 500 μM and 1 mM against all but two malignant micro-organ cultures tested in 5-10%
serum. In tests using 30-40% serum, GLA and ALA killed tumor at concentrations of 2 mM and
above.
Conclusions: The concentration threshold of 500 μM to 2 mM exhibited for antitumor activity
by GLA and ALA is much higher than that observed in most previously reported cell culture studies
but consistent with physiological concentrations found to kill tumor clinically and in animals. A
mechanism of antitumor activity by unsaturated fatty acids through selective destabilization of the
malignant plasma membrane is considered. An oral regimen is proposed for phase I clinical testing
that could push the area under the curve for serum concentration of unbound unsaturated fatty
acids over time to much higher levels than previously achieved for systemic administration and into
the range that could yield antitumor response.
Background
Unsaturated fatty acids (UFAs), including the ω-6 agent
GLA and the ω-3 agent ALA, have been observed to exhibit
cytotoxicity [1-8] or growth inhibition [9-15] against a
variety of malignant cell lines. These effects, studied
closely over the past two decades, are usually selective for
malignant versus normal cells [1-3,5,10,12,16-18]. Con-
centrations of different UFAs used in these in vitro studies
were typically no greater than 100 μM, with close to 100%
cytotoxicity achieved at concentrations of, for example,
10-12 μM [2,5], 50 μM [1] or 70 μM [19].
At low levels, ω-6 fatty acids have been shown to promote
tumor growth in some in vitro [15,20,21] and animal
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[22,23] studies. Retrospective human studies in which tis-
sue composition was analyzed have shown inverse corre-
lations of cancer incidence and ratios of ω-3 to ω-6 fatty
acids [24,25]. Benefits of ω-3 supplementation have been
demonstrated prospectively in a double-blind study of 27
patients with stage 1 or 2 colon carcinoma or adenoma-
tous polyps randomized to consume 9 grams daily of
either fish oil with high eicosapentaenoic acid content or
corn oil after surgical excision of detectable lesions. S-
phase BrdUrd labeling of tissue from proctoscopic
mucosal biopsies, a predictor for incidence of new neo-
plasms, dropped to 29% of its baseline value after six
months for the ω-3 supplemented group but rose in the
corn oil-supplemented group [26].
At higher physiological concentrations of GLA achieved
through intratumoral administration in subcutaneous
pancreatic tumors in nude mice [27] and in rat gliomas
[22,28], significant tumor shrinkage was observed. Clini-
cally, major response was reported for 15 glioma patients
who after surgery had 1 mg of GLA injected into residual
tumor daily via a cerebral catheter over 10 consecutive
days. Striking changes in CT scans indicative of response
were reported for all patients, and 28 months after study
completion, 12 surviving patients were reported under
active follow-up with no new symptoms [29]. Partial
responses of 40-60% for six glioma patients were reported
in a similar prior study [30]. A subsequent study using the
same 1 mg daily intratumoral GLA dosage over only 7
days, however, yielded lesser partial responses in 9
patients with grade 4 glioma and no survival gains
[31,32]. None of these studies were controlled clinical tri-
als.
Response was also achieved in a phase I clinical trial of
intra-vesicle treatment of superficial bladder cancer with
Meglumine GLA at concentrations of 2.4 mM or 6 mM for
a one-hour retention period. Using these high GLA con-
centrations, complete responses for 13% and partial
responses for 30% of 30 total patients were achieved [33].
But a phase III clinical trial of oral or intravenous lithium
GLA at daily doses of less than 1 g/kg for advanced pan-
creatic cancer yielded only marginal benefits [34]. Clinical
studies of low-dose oral GLA for colon [35] and liver [36]
cancer likewise yielded no benefits. These successful
results for high levels of GLA using localized treatment
approaches in contrast to negative outcomes with low lev-
els of GLA obtained using intravenous or oral systemic
administration routes are consistent with in vitro
[6,7,14,15,37] and animal [22,38] studies indicating that
UFA antitumor activity is highly dose-dependent.
A particularly sharp dose-response effect for UFA agents
was demonstrated with 16 rats treated with GLA eight
days after surgical implantation of C6 glioma tumors [22].
GLA was administered via intratumoral infusion at a flow
rate of 1 μl/h over a period of 3 or 7 days, with tumor mass
assessed the day after treatment completion. In tumors
infused with 2 mM GLA administered over 7 days, tumor
area was less than 50% of the control subgroup with
much of the tumor tissue necrotic but with intact histol-
ogy in bordering normal brain tissue. Significant tumor
growth in comparison to controls, however, was exhibited
for the 1 mM, 40 μM and 20 μM GLA concentration sub-
groups. When GLA was administered intratumorally over
3 days, tumor kill was likewise observed but to a lesser
degree at a 2 mM concentration, with growth promotion
observed at 1 mM.
To model clinical dose-response effects and explore possi-
bilities for enhanced clinical efficacy, fresh surgical
explants of malignant tumors from 22 patients were
exposed to unsaturated fatty acids at different concentra-
tions and analyzed using the Fluorescent Cytoprint Assay
(FCA). These tumors were pathologically identified as
ovarian carcinoma for 18 of the patients and as breast car-
cinoma, pancreatic carcinoma, melanoma, and glioblast-
oma, one each, for the other four. Developed in 1986 by
Boris Rotman, the FCA assesses the viability of three-
dimensional micro-organs derived from fresh surgical
human tumor explants following exposure typically to
standard chemotherapeutic agents [39,40]. This tech-
nique [41-43] and other in vitro testing systems [44,45]
have been used in clinical practice for chemosensitivity
testing since the mid-1980s. The FCA is an attractive
experimental model as it provides analytical capabilities
of standard in vitro systems, allowing about 50 or more
viability tests per specimen depending upon size of surgi-
cal explant, yet more closely simulates the physiological
environment based upon its fresh human tissue source
and three-dimensional tumor architecture.
The FCA was found 90% accurate in predicting chemo-
therapeutic treatment outcomes in a collaborative retro-
spective study [42]. Clinical response achieved for most
agents was at peak plasma levels close to concentrations
tested with the FCA procedure [42]. Although the FCA
experiments of this present study were not designed to
amass a sufficiently large set of well-structured data to
support statistical analysis, the basic dose-response char-
acteristics of UFAs that were examined are of particular
interest in light of findings indicating potential clinical
application [22,32,33] that have emerged since these
experiments were conducted.
Methods
Surgical explants
Freshly excised human tumor explants were obtained
from surgeries through the National Disease Research
Interchange (NDRI) and shipped overnight in cold cul-Lipids in Health and Disease 2009, 8:54 http://www.lipidworld.com/content/8/1/54
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ture medium. Additional specimens were obtained from
medical centers in Providence, Rhode Island associated
with the Brown University School of Medicine. Normal
stromal tissues excised in the vicinity of some tumors were
also studied. Malignant tumor specimens from 22
patients and a benign ovarian tumor specimen from an
additional patient were received and assayed between
March 1994 and March 1996. Of the 22 malignant
tumors, 18 were pathologically identified as primary or
metastatic ovarian adenocarcinoma and the others identi-
fied as breast carcinoma, pancreatic carcinoma,
melanoma, and glioblastoma (one of each). For one
patient, both primary and metastatic ovarian adenocarci-
noma was obtained and studied.
Materials
Culture chambers were constructed and fluorescein
monoacetate synthesized and purified as previously
described [39,40]. Culture medium was RPMI 1640 sup-
plemented with 5-40% fetal bovine serum (FBS) or
human serum and penicillin-streptomycin (10 U/mL)
(GIBCO, Grand Island, NY). Stock collagen solutions
were made by diluting a purified collagen (Collagen
Corp., Palo Alto., CA) solution (2 mg/ml) with 7.5 times
concentrated solution of Dulbecco's modified Eagle pow-
der medium (GIBCO), FBS, and culture medium in the
proportion 3.0: 0.5: 0.25: 1.0, respectively. The final solu-
tion was used as stock and kept at 2°C. Fresh collagenase
(Sigma, St. Louis, MO) was prepared by dissolving the
enzyme (300-350 U/mg) in culture medium and steri-
lized by passage through a 0.22 μm Vanex filter unit (Van-
guard International, Neptune, NJ).
FCA assay procedure
Processing was begun 2-5 hours after receipt of each sur-
gical explant per the methodology previously described
[39,40]. Briefly, the tissue was fragmented by first mincing
it with scalpels into pieces of about 1 mm3 and then proc-
essed for a short period (2-5 seconds) in a Tissumizer
(Tekmar). After additional processing and vital staining
with fluorescein monoacetate, tumor tissue yielded dis-
crete cellular aggregates, termed "micro-organs," that were
easily visualized and manually collected using a Pasteur
pipette. These micro-organs correspond to discrete clus-
ters of malignant cells characteristically seen in histologi-
cal preparations, most distinctly observed in carcinomas
[39]. In contrast, normal stromal tissue, not previously
studied in the FCA assay, did not naturally aggregate into
micro-organs and required additional shearing to separate
into small cellular aggregates of equivalent size (which are
also termed "micro-organs" in the discussion below).
From a typical tissue specimen, 500-700 micro-organs
were obtained, each containing 100-2000 viable cells.
Viable micro-organs were then plated as previously
described [39,40], 4-40 per micro-organ culture, with a
typical yield of 55-90 micro-organ cultures per culture
matrix. The matrix was placed on a metal grid and par-
tially submerged into growth medium and incubated at
37° under 5% CO2 for periods up to 10 days. In all exper-
iments, cultures without added test agents, typically at
least four, were used as controls to assess baseline viability
over the course of the experiment. All experiments were
performed in the laboratory of Boris Rotman at Brown
University, Providence, Rhode Island, where the FCA
assay system was used for preclinical screening of novel
anticancer agents, with specifications for agents used in
these experiments provided by the author.
Through transient, non-toxic staining by fluorescein
monoacetate, a digital image of each individual micro-
organ culture, termed a "fluorescent cytoprint," was used
to assess cytotoxicity of added agents. Fluorescent cyto-
prints were obtained for each micro-organ culture before
and after exposure to agents, and the fluorescence change
was quantitatively assessed and used as an index of viabil-
ity. Greater than 90% viability was scored "resistant;" less
than 10% viability was scored "sensitive."
Values in between were scored "intermediate," and bor-
derline values such as e.g. 85% viability were scored inter-
mediate-resistant and 15% viability scored intermediate-
sensitive. Because such intermediate values between 10%
and 90% viability (which comprised only 14% of all
reported viability results) could represent delayed cyto-
toxic effect, probabilistic variations, or tumor heterogene-
ity [39], these are less reliable indicators of the activity of
agents tested. For the purposes of charting results in the
figures shown, characterizations of sensitive, intermedi-
ate-sensitive, intermediate, intermediate-resistant, and
resistant were assigned numeric values, respectively, of 0,
0.25., 0.5, 0.75 and 1.0.
Readings were performed 5-9 days after the introduction
of agents; a 7-day period was used in all but three experi-
ments. In some experiments, additional readings were
taken between 3 and 9 days after introduction of agents.
Micro-organ cultures were typically exposed to agents
until the time of final FCA fluorescence readings. In 33
micro-organ cultures from three malignant specimens,
agents were replaced with culture media after a 2-day
period, and in 36 micro-organ cultures from two malig-
nant specimens, agents were replaced with culture media
after a 5-day period.
UFAs and other agents used
In the first four experiments, GLA and ALA were studied
either as lithium salts or as free fatty acids dissolved 40
mg/ml in ethanol and then added to culture media in aLipids in Health and Disease 2009, 8:54 http://www.lipidworld.com/content/8/1/54
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stable suspension to achieve desired agent concentrations,
per a methodology used in some prior in vitro studies
[17,46]. In subsequent experiments, all tests were per-
formed using the sodium salts of GLA and ALA to pre-
clude any possible active effects of ethanol or lithium (no
differences in results for the different forms of these agents
were in fact observed). Linoleic acid (LA), eicosapentae-
noic acid (EPA), and oleic acid (OA) were also tested
using their sodium salts. LA and EPA were tested as single
agents, and mixtures of ALA, GLA, LA, and OA approxi-
mately simulating typical compositions of dietary oils
were also tested. (All UFAs were obtained from Nu-Chek
Prep, Elysian, New York.)
In addition, various agents such as epinephrine, acetylsal-
icylic acid, caffeine and lithium were tested in combina-
tion with UFAs for potential synergistic effects using extra
available micro-organ cultures, but inconclusive results of
these multi-agent tests are not reported.
Results
Figs 1, 2, 3 and 4 show FCA analysis of viability for 282
micro-organ cultures derived from tumors of five malig-
nant types (ovarian adenocarcinoma, breast carcinoma,
pancreatic carcinoma, melanoma, and glioblastoma) that
were surgically excised from 22 patients and exposed to
GLA and ALA at different concentrations. FCA results for
normal stromal tissue are also shown in Fig. 1. Additional
results for a benign ovarian tumor from another patient,
for two other normal stromal tissue specimens, and for
tests of other UFAs and UFA mixtures are summarized but
not shown.
Fig. 1 shows cytotoxic activity of UFAs exposed to ovarian
carcinoma (Fig. 1A, 1B), glioblastoma (Fig. 1C) and nor-
mal stromal tissue (Fig. 1D), all cultured in 10% fetal calf
serum. Tumor kill is exhibited at a sharp concentration
threshold of 500 μM for ALA in Fig. 1A and for GLA in Fig.
1C and at a sharp concentration threshold of 1 mM for
Cytotoxic activity of UFAs exposed to micro-organs from malignant and normal tissue explants Figure 1
Cytotoxic activity of UFAs exposed to micro-organs from malignant and normal tissue explants. A: Viability val-
ues (0 = sensitive, 1 = resistant) are shown for a metastatic ovarian tumor exposed to GLA (black square) and ALA (Grey 
square); 26 controls (represented as 0 μM GLA) were all viable. B: Results for a primary ovarian tumor. Viability values of 0 at 
2 mM (two each for GLA, ALA) are not shown. Four control values were 1.0 (3) and 0.75 (1). C: Results for a glioblastoma 
tumor; 6 control were all viable. D: Results for a normal stromal tissue specimen; all 4 controls were viable. A numeric pair (m, 
n) depicts m and n identical results, respectively, for GLA and ALA represented by the bar below. All four experiments used 
10% fetal calf serum.
B.
C. D.
A.Lipids in Health and Disease 2009, 8:54 http://www.lipidworld.com/content/8/1/54
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GLA and ALA in Fig. 1B, for GLA in Fig. 1A, and for ALA
in Fig. 1C. Cytotoxic activity of UFAs exposed to normal
stromal tissue shown in Fig. 1D is in about the same con-
centration range as for malignant tumors. Similar results,
not shown, were obtained for two other normal stromal
tissue explants and for one benign ovarian tumor. As
detailed in the caption for Fig. 1, 39 of 40 control micro-
organ cultures in these experiments had viability value 1
(resistant) and one had viability value 0.75.
Figs 2 and 3 show aggregate data for malignant tumors
tested in 5-10% fetal calf and in 5-10% human serum,
respectively. As discussed in methods, intermediate viabil-
ity readings in these and Fig. 4, which were assigned val-
ues of 0.25, 0.5, and 0.75 for charting purposes and which
comprise only 14% of all reported viability values, are less
reliable indicators of agent effects in vivo than sensitive or
resistant readings. While the complete set of viability val-
ues is thus not amenable to close data analysis, the signif-
Aggregate data for UFA exposure to micro-organs from malignant tumor explants in 5-10% fetal calf serum Figure 2
Aggregate data for UFA exposure to micro-organs from malignant tumor explants in 5-10% fetal calf serum. 
Viability values are shown for 153 micro-organ cultures from malignant tumors exposed to GLA (Black square) or ALA (Grey 
square) in 5% or 10% fetal calf serum. Tumor types tested, as detailed under methods, were ovarian adenocarcinoma, breast 
carcinoma, pancreatic carcinoma, melanoma, and glioblastoma. Parenthesized values above bars here and in the following two 
figures represent multiple data points as in Fig. 1. For example, at a 50 μM GLA concentration, the viability readings were 1.0 
(resistant) for 4 micro-organ cultures, 0.5 (intermediate) for 2, and 0.25 (intermediate-sensitive) for 1.
Aggregate data for UFA exposure to micro-organs from malignant tumor explants in 5-10% human serum Figure 3
Aggregate data for UFA exposure to micro-organs from malignant tumor explants in 5-10% human serum. Via-
bility values are shown for 103 micro-organ cultures from malignant tumors exposed to GLA (Black square) or ALA (Grey 
square) in 5% or 10% human serum. (Two viability readings of 0 for 2.5 mM GLA are not shown.)Lipids in Health and Disease 2009, 8:54 http://www.lipidworld.com/content/8/1/54
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icant feature in Figs 2 and 3 is the drop in these values
from mostly 1 (resistant) at GLA or ALA concentrations of
250 μM or below to 0 (sensitive) at concentrations of 1
mM and above (with the exception of two viability values
of 0.25 for ALA at 1 mM shown in Fig. 2).
Each malignant tumor tested using 5-10% fetal calf or
human serum exhibited a sharp cytotoxic concentration
threshold between 500 μM and 1 mM for GLA and ALA,
varying by explant and agent. With the two exceptions
noted above, viability values were 0 at and above this con-
centration threshold, but were usually 1 below 50% of
that concentration.
For experiments conducted in 30% or 40% human serum,
cytotoxic activity was consistently observed for GLA and
ALA at but not below a 2 mM concentration (Fig. 4). Iso-
lated tests (not shown) for a total of 60 micro-organ cul-
tures from 8 surgical explants using eicosapentaenoic acid
(EPA), linoleic acid (LA), and various mixtures of LA, oleic
acid (OA), GLA and/or ALA, including ALA, LA and OA in
proportions approximately simulating flaxseed oil com-
position indicate cytotoxic activity consistent with that for
GLA and ALA (comparing total molarities of UFAs for
mixed agents).
Micro-organ cultures were generally exposed to agents
throughout the 7-day duration of the experiment, with a
2-day exposure period used for 33 micro-organ cultures
from three malignant specimens and a 5-day exposure
period used for 36 micro-organ cultures from two malig-
nant specimens. No study of the relationship between
activity and exposure time was performed, but no differ-
ences in cytotoxic activity of GLA and ALA based upon
varying exposure times were apparent.
Discussion
It is noteworthy that for each of 22 surgical explants of five
malignant types, GLA and ALA each exhibited greater than
90% cytotoxic activity at a sufficiently high concentration
threshold. These concentration thresholds for antitumor
activity, however, ranging from 500 μM to 2 mM depend-
ing upon explant, agent and serum concentration, are
much higher than the UFA concentrations of 10 to 100
μM observed to kill tumor in most previously reported in
vitro studies using tissue culture cells [1,2,5,19].
These FCA findings, however, are consistent with clinical
and animal studies in which tumor shrinkage was
achieved using localized administration methods [22,27-
29,33] providing UFA concentrations as high as 6 mM
[33] but not using systemic agent delivery [34-36]. Of par-
ticular interest is the parallel to the rat glioma study cited
earlier, in which tumor kill but no damage to adjoining
normal tissue was observed using 2 mM but not lower
concentrations of intratumorally infused GLA [22].
FCA results for normal stromal tissue, on the other hand,
support no clear interpretation, since such tissue does not
naturally aggregate into micro-organs, has not been previ-
ously studied in the FCA assay, and has no record of pre-
dictive accuracy for agent effects on normal tissue in vivo.
Viability values showing cytotoxicity for normal stromal
tissue in the same UFA concentration range as for malig-
nant tissue are also inconsistent with in vitro [1-
3,5,10,12,16-18], animal [22] and clinical [29,33] find-
ings demonstrating full viability of normal tissue at UFA
concentrations that killed malignant cells, as high as 2
mM [22] to 6 mM [33]. Nevertheless, these FCA results for
normal tissue raise the possibility that the cytotoxic effects
observed in all reported FCA tests could represent nonse-
lective cell damage caused by UFA agents at high concen-
trations.
Alternatively, UFA cytotoxicity to normal tissue could
potentially be associated with alterations of the extracellu-
lar cell matrix (ECM) caused, for example, by tissue dis-
ruption during Tissumizer processing or other assay
preparations. The difficulties of simulating the physiolog-
ical ECM and of maintaining viability for normal cells in
culture have been noted [47]. These considerations sug-
gest the hypothesis that fluidization of the plasma mem-
brane caused by UFAs [21,48,49] is a key event triggering
ultimate tumor cell death, as has been proposed [50,51].
Malignant cells are characterized by a disorganized ECM
[52-56] and supporting cytoskeleton [56-59], in sharp
contrast to the well-structured such components of nor-
mal cells. Surface bleb formation has been observed
beginning as early as 15 minutes after viral transformation
to the malignant state [53,56-59]. Some studies indicate
Aggregate data for UFA exposure to micro-organs from  malignant tumor explants in 30-40% human serum Figure 4
Aggregate data for UFA exposure to micro-organs 
from malignant tumor explants in 30-40% human 
serum. Viability values are shown for 22 micro-organ cul-
tures from malignant tumors exposed to GLA (Black square) 
or ALA (Grey square) in 30% or 40% human serum. (Viability 
readings of 0 for 4 mM GLA and ALA, one each, are not 
shown.Lipids in Health and Disease 2009, 8:54 http://www.lipidworld.com/content/8/1/54
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that malignant cells have more rigid plasma membranes
than normal cells [52] with 2-3 times higher cholesterol
content [60], which could perhaps be compensatory for
decreased stability of the ECM and cytoskeleton.
Pronounced changes in membrane lipid composition of
cultured tumor and normal cells result from UFA supple-
mentation of culture media. Multifold increases in mem-
brane free fatty acid percentages corresponding to added
UFAs are observed within hours [61-64]. With UFA added
at a 300 μM concentration, the corresponding percentage
of total membrane lipids reaches as high as 60% [63].
Membrane lipid changes are 90% complete within about
16 hours [61-64] and persist at least 48-72 hours in
unsupplemented culture media [64].
Malignant cell membranes, however, exhibit more pro-
nounced ultimate changes in lipid composition corre-
sponding to ingested UFAs in dietary supplementation
studies [60] than do normal cell membranes, and achieve
greater fluidization upon exposure to UFAs [21,60]. Sup-
plementation by ALA or oleic acid, in particular, caused
fluidization and destabilization in model membranes, an
effect related to the hook and boomerang shapes, respec-
tively, of these molecules [65]. Sharp peaks of membrane
fluidization were observed in cultured human cancer cell
membranes 3 days after exposure to ALA [21] and to lino-
leic acid [49] with a less pronounced peak for oleic acid at
2-4 days [49].
Apoptosis observed after exposure of malignant cells to
UFAs [6,9,14,15,22,66] could thus be triggered by a criti-
cal membrane destabilization event resulting from defi-
ciencies in ECM structure and in homeostatic control of
membrane fluidity. Tumor cells packed in a tight array
could be less vulnerable to membrane destabilization,
which would be consistent with the observation that the
concentration threshold for significant GLA effect against
gliomas varied from 20 μM for monolayer cultures to 200
μM for three dimensional spheroid preparations and 2
mM in vivo [66].
If these FCA assay results are predictive of UFA serum lev-
els required for clinical response, as has been the case for
other chemotherapeutic agents [42], they present a partic-
ular challenge for successful systemic clinical treatment.
Albumin sharply attenuates the antitumor activity of
UFAs [8,67,68], consistent with FCA assay results noted
above showing significantly diminished GLA and ALA
activity in 30-40% human serum. Whether intravenous or
oral UFA delivery was used, rapid binding of UFA agents
to albumin in serum would significantly reduce serum
levels of the active unbound form. This constitutes a sig-
nificant limitation given that under normal conditions,
total human serum free fatty acid concentration is about
300 μM [69].
Duration of elevated UFA serum levels also appears to be
a significant factor in clinical efficacy, as suggested by time
and concentration studies using bladder cancer cell lines
with viability measured five days after agent exposure.
Tumor kill was achieved with 30-minute exposure to GLA
at 1 mM, 1 hour at 500 μM or 2 hours at 125 μM [7], dem-
onstrating a more than linear advantage for application
over an extended time frame. This increased cytotoxic
effect with longer exposure period is consistent with the
time frame of membrane UFA absorption noted earlier,
with changes in lipid composition reaching a plateau at
about 16 hours and persisting at least 2-3 days.
A proposed approach for achieving sustained high serum 
levels of unbound UFAs
One approach for achieving high serum levels of
unbound UFAs over an extended time period is to utilize
three concurrent physiological perturbations in conjunc-
tion with high-dose UFA ingestion: fasting, exercise and
caffeine. These and high-dose ingested UFA can each
boost serum free fatty acid levels by up to 100%, and com-
binations can elevate total serum free fatty acid levels into
the 1-2 mM range [70-78]. Flaxseed oil, a triglyceride
blend consisting of about 58% ALA, 19% oleic acid, 14%
linoleic acid and 9% saturated fatty acids, would provide
a safe dietary UFA source. This oil, with its high ratio of ω-
3 to ω-6 components, would not be subject to risks of
tumor growth promotion at suboptimal levels as noted
earlier for ω-6 agents [15,20-23].
Specifically, these combined elements could be provided
through a regimen consisting of an overnight fast and
then ingestion of flaxseed oil without added vitamin E or
other antioxidants at 3.33 grams per kilogram of body
weight between 9-10 AM, followed by 200 mg caffeine
dosages at 10 AM and again at 11 AM. Beginning at 11
AM, the subject would exercise for 90 total minutes, with
intermittent short rest periods as needed, at moderate
intensity, e.g., at 55% of VO2max or 70% of maximum
heart rate, within the limits of the subject's capability. The
fast would then terminate at 6 PM. This schedule would
be repeated over three consecutive days. Given unknown
risks, this regimen would be suitable only for application
in a clinical study involving subjects having no proven
treatment options, with daily complete blood counts con-
ducted and other precautions taken.
Combined fasting, exercise and caffeine in untrained
women per specifications similar to the above, but with-
out fat ingestion, resulted in serum free fatty acid levels
averaging 1.9 mM [73]. Increased free fatty acid serum lev-
els achieved under such conditions persisted for severalLipids in Health and Disease 2009, 8:54 http://www.lipidworld.com/content/8/1/54
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hours with continued fasting [75,77]. It thus appears that
total serum free fatty acid levels of at least 1.5 mM could
be obtained between 1 and 6 pm each day of this pro-
posed regimen, with about half of serum fatty acids con-
sisting of UFAs from flaxseed oil, as can be roughly
projected based on oral ingestion studies of 30-40 grams
[79] or 100 grams [71] of fats. This would yield a concen-
tration of at least 750 μM for unbound UFAs in serum
during a total period of 15 total hours over three consecu-
tive days. Note that this figure of 750 μM is appropriately
compared to the UFA tumor kill concentration threshold
of 500 μM to 1 mM for FCA tests using low serum concen-
trations, since unbound UFA concentrations in FCA tests
using high serum concentrations would be significantly
diminished by albumin binding.
Several physiological potentiating factors could enhance
clinical efficacy. Lipid peroxidation, which has been
found to sharply promote UFA antitumor activity [1-
5,11,16,19,46,80-82], could be triggered clinically by
reactive oxygen and nitrogen species released during
immune surveillance of tumor cells [83]. Changes in
plasma membrane shape during mitosis could yield addi-
tional vulnerability to UFA-induced membrane destabili-
zation for tumor cells in that phase of the cell cycle. This
could in turn result in propagating death in neighboring
cells through a cascade of released lipid peroxidation
products.
Elevated local concentrations of free fatty acids would
occur in tumors as a consequence of increased secretion of
lipoprotein lipase [84], which may be caused by increased
metabolic requirements of malignant cells and may thus
be more pronounced under fasting conditions. In addi-
tion, plasma membrane lipid turnover would be
increased by caffeine at moderate dosages [85,86], while
exercise and caffeine would yield an increased ratio of
unsaturated to saturated fatty acid levels in serum [75].
Lymphatic transport of ingested lipids may yield
increased levels of UFAs in the intestine or peritoneal cav-
ity, which would provide an advantage against tumors in
those anatomical regions.
Finally, additional possibilities for clinical benefits are
raised by findings that multidrug resistant (MDR) malig-
nant cell lines were as sensitive [7,14,87] or more sensitive
[88] to UFA agents than their non-MDR counterparts and
that drug resistance could be reversed by UFA application
[51,89,90]. This suggests the possibility that should the
proposed 3-day combination regimen fail to achieve
response, it could still potentially reverse drug resistance
in MDR tumor cells or selectively target them and allow
response to be achieved in subsequent chemotherapy
treatments.
A preliminary test of feasibility of the proposed combina-
tion of high-dose flaxseed oil, fasting, exercise and caf-
feine was conducted for one day only in 2006 by an
ovarian cancer patient whose tumor markers had begun to
progress during a second chemotherapy regimen. Four
months after the last treatment in this regimen, after being
warned of unknown risks of this dietary intervention, the
patient began an overnight fast and the next morning
ingested 225 grams of flaxseed oil plus 100 mg caffeine
followed by light exercise and hourly intake of caffeine in
a total additional dose of 800 mg over a 6-hour period,
after which the fast was terminated.
The patient was able to ingest the flaxseed oil without dif-
ficulty, with palatability improved by being blended with
a few tablespoons of non-fat yogurt, sweetener and ice
cubes to a flowing consistency. A transient drop in CA125
tumor marker level followed this treatment (CA125 val-
ues for 54, 28 and 5 days before treatment and then 8 and
28 days after treatment were, respectively, 31, 55, 77 and
then 40 and 66). Two subsequent repetitions of this die-
tary intervention without full adherence to fasting caused
no reduction in steadily increasing tumor marker values.
The patient subsequently responded to a different chemo-
therapy regimen and survived two additional years.
Although burdensome for patients and subject to signifi-
cant individual variations in unbound UFA serum levels
achieved, the proposed 3-day regimen can provide a
mechanism to initially test whether UFAs at high
unbound serum levels over an extended period could
yield clinical response. Stage III ovarian cancer patients
with recurrent or multi-drug resistant disease, as indicated
by rising CA-125 tumor marker values, would be ideal
subjects for a clinical trial given their typically high per-
formance status, lack of proven curative options, location
of tumor in the peritoneal cavity, and ability to track
response through monthly CA-125 blood test results.
High serum concentrations of unbound UFAs can also be
achieved using combined intravenous administration of a
lipid emulsion and heparin. Studies using Intralipid and
heparin administered intravenously to normal volunteers
yielded total serum free fatty acid levels of 1.3 mM [91]
and 1.67 mM [92] respectively 3 and 5 hours after initia-
tion of infusion. Also, a custom UFA blend could prove
more effective than flaxseed oil, for example, with GLA
and EPA substituted for linoleic acid and saturated fatty
acid components. For initial testing, however, the pro-
posed combination of oral flaxseed oil, fasting, exercise
and caffeine would appear to offer less risk of unknown
adverse effects and also the potentiating factors cited
above.Lipids in Health and Disease 2009, 8:54 http://www.lipidworld.com/content/8/1/54
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Should sustained high serum levels of unbound UFAs
achieved through some such approach yield major
response, it would be of particular interest to explore
whether aberrant properties of the malignant plasma
membrane and ECM that are in some cases independent
of genomic instability [93] could underlie such effects. It
has been demonstrated, for example, that one dose of ion-
izing radiation to nonmalignant human mammary epi-
thelial cells causes heritable loss of organization, aberrant
cell-to-ECM interactions and loss of tissue specific archi-
tecture in progeny of irradiated cells, all characteristic of
neoplastic progression, but without the occurrence of
genetic changes [94].
In a series of studies, Clarence Cone [95,96] demonstrated
differences in transmembrane voltage and associated
ionic concentrations between normal and malignant cells
and was able to influence mitotic behavior by experimen-
tal manipulation of these environmental factors. Nuclei of
malignant cells transplanted into normal oocytes in frogs
or mice have yielded, respectively, fully functional tad-
poles [97] or post-implantation mouse embryos with
high [98] or mixed [99] degrees of tissue development.
Many studies that illuminate non-genomic, membrane-
related characteristics of malignancy have been compre-
hensively reviewed [100].
Conclusions
A sharp, high tumor kill concentration threshold for GLA,
ALA, and other UFAs was determined using fresh human
tumor explants analyzed with the clinically predictive FCA
assay system. This concentration threshold of 500 μM to
2 mM for antitumor activity, depending upon explant,
agent and serum concentration, is consistent with in vivo
and clinical results and indicates a need for a dose-inten-
sive approach in the application of UFAs to cancer treat-
ment.
An oral clinical regimen is proposed that could push the
area under the curve for serum concentration of unbound
UFAs over time to much higher levels than previously
achieved and into the range that could yield clinical
response. If safety is demonstrated and if response is
achieved for some patients, efficacy could potentially be
achieved more consistently and patient burden dimin-
ished with intravenous administration of a UFA emulsion
and heparin, as noted above.
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